Vital Signs - Life Sciences and Drug Discovery Technologies Market Consolidation - Unique Aims of Mergers & Acquisitions

 


This issue of Vital Signs, released on April 9, 2007, provides a strategic overview of the impact of consolidation in the life sciences and drug discovery technologies market. Additionally, an emerging company profile is provided for Network Biosystems, a developer of DNA analysis technologies for forensics, clinical diagnostics, homeland security, and genomic sequencing applications. Reimbursement and regulatory news from the FDA and CMS is also provided for the week of March 26 - March 30, 2007.

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

Table of Contents

Vital Signs - Life Sciences and Drug Discovery Technologies Market Consolidation - Unique Aims of Mergers & AcquisitionsVital Signs: 9 April 2007This week's issue:




Related Research

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Release Date : 24-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.